NEW YORK (TheStreet) -- RATINGS CHANGES Allergan was downgraded at Credit Suisse to neutral from outperform. Twelve-month price target is $190. Risk/reward is balanced, following the latest bid from Valeant , Credit Suisse said. Big Lots was downgraded to hold at TheStreet Ratings. Broadcom was downgraded at Stifel to hold from buy, Stifel Nicolaus said. Valuation call, based on a 12-month price target of $35, Stifel Nicolaus said. Broadcom was upgraded at Wedbush to outperform from neutral. Twelve-month price target is $43. Company is looking to sell or wind down the cellular baseband business, which has been an overhang, Wedbush said. [Read: Broadcom's a Buy Now] Chico's FAS was downgraded to hold at TheStreet Ratings. Clovis was downgraded at Citigroup to neutral. Twelve-month price target is $53. Company could face increased competition from AstraZeneca , Citi said. Centene was downgraded at Citigroup to sell. Takeover rumors will likely fizzle out, Citi said. [Read: Whom Should You Trust With Your Money? Teenage Girls, Apparently] Devon Energy was upgraded at Wells Fargo to outperform from market perform. Production visibility is improving, Wells Fargo said. Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here. Follow TheStreet on Twitter and become a fan on Facebook. >>Read More: Banks Face Serious Threat in the Second Half >>Read More: Greenberg: Apple's Latest Ad-Stravaganza
Click to view a price quote on AGN. Click to research the Drugs industry.
from Latest TSC Headlines http://ift.tt/1rH7eJJ
No comments:
Post a Comment